BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 22315094)

  • 21. Study of T lymphocytes infiltrating peritoneal metastases in advanced ovarian cancer: associations with vascular endothelial growth factor levels and prognosis in patients receiving platinum-based chemotherapy.
    Tsiatas ML; Gyftaki R; Liacos C; Politi E; Rodolakis A; Dimopoulos MA; Bamias A
    Int J Gynecol Cancer; 2009 Nov; 19(8):1329-34. PubMed ID: 20009885
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
    Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
    BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
    McCluggage WG
    Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low expression of miR-449 in gynecologic clear cell carcinoma.
    Jang SG; Yoo CW; Park SY; Kang S; Kim HK
    Int J Gynecol Cancer; 2014 Nov; 24(9):1558-63. PubMed ID: 25238166
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo.
    English DP; Bellone S; Schwab CL; Roque DM; Lopez S; Bortolomai I; Cocco E; Bonazzoli E; Chatterjee S; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
    Cancer; 2015 Feb; 121(3):403-12. PubMed ID: 25251053
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Musashi-2 is a novel regulator of paclitaxel sensitivity in ovarian cancer cells.
    Lee J; An S; Choi YM; Lee J; Ahn KJ; Lee JH; Kim TJ; An IS; Bae S
    Int J Oncol; 2016 Nov; 49(5):1945-1952. PubMed ID: 27600258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytologic study of ascites and the endometrium in ovarian carcinoma. Clinical significance.
    Hirasawa T; Yasuda M; Muramatsu T; Itoh H; Shinozuka T; Makino T; Tsutsumi Y; Osamura RY
    Acta Cytol; 1997; 41(5):1451-5. PubMed ID: 9305383
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients.
    Rao ZY; Cai MY; Yang GF; He LR; Mai SJ; Hua WF; Liao YJ; Deng HX; Chen YC; Guan XY; Zeng YX; Kung HF; Xie D
    Carcinogenesis; 2010 Sep; 31(9):1576-83. PubMed ID: 20668008
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overexpression of salusin-β is associated with poor prognosis in ovarian cancer.
    Zhang Q; Chen WM; Zhang XX; Zhang HX; Wang HC; Zheng FY; Zhu FF
    Oncol Rep; 2017 Mar; 37(3):1826-1832. PubMed ID: 28184918
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma.
    Elloul S; Elstrand MB; Nesland JM; Tropé CG; Kvalheim G; Goldberg I; Reich R; Davidson B
    Cancer; 2005 Apr; 103(8):1631-43. PubMed ID: 15742334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of the clinicopathological relevance of mesothelin level in plasma, peritoneal fluid, and tumor tissue of epithelial ovarian cancer patients.
    Okła K; Surówka J; Frąszczak K; Czerwonka A; Kaławaj K; Wawruszak A; Kotarski J; Wertel I
    Tumour Biol; 2018 Oct; 40(10):1010428318804937. PubMed ID: 30319054
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gene expression profiles in three histologic types, clear-cell, endometrioid and serous ovarian carcinomas.
    Pamuła-Piłat J; Rubel T; Rzepecka IK; Olbryt M; Herok R; Dansonka-Mieszkowska A; Grzybowska E; Kupryjańczyk J
    J Biol Regul Homeost Agents; 2014; 28(4):659-74. PubMed ID: 25620176
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer.
    Negus RP; Stamp GW; Relf MG; Burke F; Malik ST; Bernasconi S; Allavena P; Sozzani S; Mantovani A; Balkwill FR
    J Clin Invest; 1995 May; 95(5):2391-6. PubMed ID: 7738202
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lost expression of DCC gene in ovarian cancer and its inhibition in ovarian cancer cells.
    Meimei L; Peiling L; Baoxin L; Changmin L; Rujin Z; Chunjie H
    Med Oncol; 2011 Mar; 28(1):282-9. PubMed ID: 20054719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of CC chemokine and chemokine receptor expression in solid ovarian tumours.
    Scotton C; Milliken D; Wilson J; Raju S; Balkwill F
    Br J Cancer; 2001 Sep; 85(6):891-7. PubMed ID: 11556842
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients.
    Obermayr E; Sanchez-Cabo F; Tea MK; Singer CF; Krainer M; Fischer MB; Sehouli J; Reinthaller A; Horvat R; Heinze G; Tong D; Zeillinger R
    BMC Cancer; 2010 Dec; 10():666. PubMed ID: 21129172
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HSP60 predicts survival in advanced serous ovarian cancer.
    Hjerpe E; Egyhazi S; Carlson J; Stolt MF; Schedvins K; Johansson H; Shoshan M; Avall-Lundqvist E
    Int J Gynecol Cancer; 2013 Mar; 23(3):448-55. PubMed ID: 23429486
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer.
    Woopen H; Pietzner K; Richter R; Fotopoulou C; Joens T; Braicu EI; Mellstedt H; Mahner S; Lindhofer H; Darb-Esfahani S; Denkert C; Sehouli J
    J Gynecol Oncol; 2014 Jul; 25(3):221-8. PubMed ID: 25045435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome.
    Byrne JA; Maleki S; Hardy JR; Gloss BS; Murali R; Scurry JP; Fanayan S; Emmanuel C; Hacker NF; Sutherland RL; Defazio A; O'Brien PM
    BMC Cancer; 2010 Sep; 10():497. PubMed ID: 20846453
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A critical role of Oct4A in mediating metastasis and disease-free survival in a mouse model of ovarian cancer.
    Samardzija C; Luwor RB; Volchek M; Quinn MA; Findlay JK; Ahmed N
    Mol Cancer; 2015 Aug; 14():152. PubMed ID: 26260289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.